BioCrossroads has established itself as a leading source of venture capital for Indiana’s life sciences industry through the formation of four life sciences focused, return-driven investment funds. BioCrossroads has also been strongly supported by Indiana’s corporate and academic life sciences leadership, and has partnered with these stakeholders in several ways, including investment and enterprise-formation activities. BioCrossroads is in a strong position to continue to grow Indiana’s life science industry through the identification, advancement, and investment in Indiana’s science and technology innovations
Indiana Seed Funds
BioCrossroads has established two early-stage life sciences venture funds focused on identifying, creating and developing the next generation of leading lndiana-based companies – the $6 million Indiana Seed Fund I (2005) and the $8 million Indiana Seed Fund II (2012). Managed by BioCrossroads, the Funds make investments in early-stage biotechnology, pharmaceutical, medical device, diagnostic, ag-biotech and health information technology products and platforms and will continue to focus on forming promising companies around innovative ideas. To be considered for investment, companies are expected to have proven management teams, owned or licensed technology, intellectual property, and be able to demonstrate a validated market need. Ideal companies will be progressing towards defined milestones to secure a Series A financing, strategic partnership or co-development agreement.
Indiana Seed Fund I (fully invested)
Indiana Seed Fund II
Venture Capital Funds
In 2003, BioCrossroads established the Indiana Future Fund I as a leading source of venture financing for Indiana opportunities. The Indiana Future Fund I is a $73 million fund of funds that is managed by AlpInvest Partners. In December 2009, BioCrossroads established a successor fund – the $58 million INext Fund. As with the Indiana Future Fund, the INext Fund is organized as a return-driven, fund of funds that is also managed by AlpInvest Parners.